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Polyphenols are natural compounds presents in fruits and vegetables that can exert beneficial effects on 
human health and notably, on the cardiovascular system. Some of these compounds showed significant 
protective activities toward atherosclerosis, hypertension, myocardial infarction, anthracyclin-induced 
cardiomyopathy, angiogenesis as well as heart failure. Polyphenols can act through systemic effects as 
well as through modulation of signaling pathways such as redox signaling, inflammation, autophagy and 
cell death in the heart and vessels. These effects can be mediated by changes on expression level and by 
post-translational modifications of proteins (e.g. Stat1, CaMKII, Sirtuins, BCL-2 family members, 
PDEs, TRF2, eNOS and SOD). This non-comprehensive short review aims to summarize recent 
knowledge on the main pharmacological effects and mechanisms of cardioprotection of pure 















Nowadays, cardiovascular diseases (CVD) constitute a major health problem and have become the 
largest single contributor worldwide of non-communicable deaths accounting for more than 50% [1]. 
CVD are a group of disorders affecting the heart and blood vessels, and include diseases and/or 
syndromes such as atherosclerosis, hypertension, ischemic coronary and heart diseases, myocardial 
infarction and heart failure (HF) [1]. Most of these diseases are heterogeneous conditions with diverse 
etiologies and comorbidities, generally aggravated by age and risk factors such as hereditary factors, 
sex, tobacco, unhealthy diet, physical inactivity, cholesterol, alcohol and hypertension (Figure 1). Due 
to their prevalence and their anticipated increase in the next decade, the study of CVD and the search 
for better prevention and treatments have recently regain interest in academic and pharmaceutical 
sectors.  
CVD share common pathological mechanisms, but each pathology has also its own specificities, 
mechanisms and comorbidities. Thus, it is admitted that myocardial infarction results from events of 
ischemia and reperfusion (I/R) affecting the blood flow through vessels and the heart [2]. Most of the 
time, this implies four sequential phases of vascular and cardiac alterations: (i) development of 
atherosclerotic plaque within the vessel, (ii) atherosclerotic plaque rupture and thrombosis, (iii) acute 
tissue and cellular damage due to the reperfusion of the heart following ischemia and (iv) chronic tissue 
remodeling. These phases are also associated with hypertension, cardiac hypertrophy, oxidative stress, 
inflammation, cell death and fibrosis. All these damages contribute ultimately to cardiac dysfunction 
with a decrease in ejection fraction and can lead to arrhythmias. This cardiac remodeling can evolve 
during several years and can lead to HF, acute decompensated HF and ultimately patient death [2]. Of 
note, HF and congenital cardiomyopathies can also occur independently of myocardial infarction 
depending on patient history and risk factors (Figure 1).  
Due to their complexity, heterogeneity and co-morbidities, CVD are difficult to treat, and drug 
combinations are frequently necessary to address the various causes and symptoms. For example, 
irrespective of specific country health rules, a variable combination of vasodilators, beta-blockers, 
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angiotensin-converting enzyme inhibitors, diuretics, aldosterone antagonists, inotropes and 
thrombolytics are recommended to treat CVD patients.  
Strong evidence from observational studies and meta-analyses have revealed a positive correlation 
between greater intake of fruits and vegetables and a decreased prevalence of CVD [3]. Fruits and 
vegetables are characterized by low caloric density and can provide dietary fibers, essential vitamins 
and minerals, which are beneficial nutrients and low-energetic constituents. Moreover, they are 
exclusive and rich sources of a wide variety of phytochemicals, including polyphenols, carotenoids, 
plant sterols, and glucosinolates. Although not strictly essential micronutrients, some of these 
phytochemicals can contribute to a healthy body weight, desirable lipid profile and blood pressure (BP) 
[4, 5]. Understanding which are the most promising cardioprotective compounds in the diet is therefore 
of great interest to international health organizations and governments, in order to plan public health 
strategies and interventions to combat the growing global CVD burden [1].  
In this context, polyphenols have been proposed to exert beneficial effects on the prevention of CVD 
and treatment via ability to prevent them and favor repair processes of heart and vessels. Indeed, research 
undertaken during the last decades demonstrated that they can have pleiotropic roles in controlling 
cardiac apoptosis, inflammation, endothelium integrity and oxidative stress [2, 6]. The underlying 
mechanisms are believed to include effective inhibition of low density lipoprotein (LDL) oxidation, a 
key process in the onset of atherosclerosis [7]. In addition, polyphenols have beneficial effects on platelet 
aggregation and thus participate to the regulation of BP [8]. Moreover, certain polyphenols prevent 
pathological cardiac remodeling, which includes effects on cardiac hypertrophy, cardiac dilatation and 
fibrosis [9]. Altogether, despite the fact that numerous cellular and molecular mechanisms remain 
unknown, some studies support that polyphenols play a critical role in cardioprotection [10]. 
Polyphenols are natural compounds largely found in plants (Figure 2). They are characterized by the 
presence of one or several phenolic groups linked to one hydroxyl functional group (-HO) that can be 
associated into complex structures [9, 11]. Not all present structural characteristics of polyphenols but 
are commonly integrated in the group of polyphenols as “honorary”, which is the case of phenolic acids 
and stilbenes [12-14]. Polyphenols are an extremely diversified group in terms of chemical structure. 
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They include 4 classes, namely flavonoids, stilbenes, phenolic acids and lignans and 6 sub-classes of 
flavonoids, including flavonols, flavones, flavanones, flavanols, isoflavones and anthocyanins [11]. 
From almost all classes, compounds with cardioprotective properties have been identified. A scheme of 
the polyphenol classification and the chemical structure of main compounds that are discussed in the 
review are presented in figure 2.  
Polyphenols have been studied either in a pharmacological or nutritional perspective for their influence 
on CVD [15, 16]. Some meta-analysis of randomized controlled trials (RCTs) confirmed the validity of 
individual studies, with particularly strong evidence existing for cocoa and tea flavanols [17-19]. Of 
note, the polyphenols most commonly ingested in the human diet are not necessarily the most active 
within the body. The extensive and rapid metabolism to which dietary polyphenols are submitted once 
ingested, either in the gastrointestinal tract, microbiota, liver, and or in cells, leads to the appearance of 
a broad range of new polyphenol metabolites. In order to assess the efficacy of polyphenols, and to be 
able to use them as therapeutic molecules, it is important to conduct studies with pure or purified 
compounds. Recently, novel strategies to supply pure polyphenols to humans and avoid their extensive 
metabolism have been emerging since there is increasing evidence of their pharmacological potential. 
Formulations and methods for enhancing polyphenols bioavailability, solubility and stability in the 
human body have been patented, creating new derivatives with improved biological activity and stability 
[20]. Besides the form of delivery/route of administration, administration of pure compounds is an 
attractive alternative to the use of mixtures or whole extracts in a pharmacological perspective, even if 
very few human trials have been conducted with the various classes of polyphenols as pure compounds.  
The aim of this review is to highlight and discuss some recent knowledge on cellular, animal and human 
studies conducted with pure polyphenols to delineate their main pharmacological mechanisms of 
cardioprotection and identify their putative targets. We will not address nutritional studies where the 
effect of dietary polyphenols in foods are considered, or the effect of nutritional relevant polyphenol 
metabolites in cellular system, or polyphenols ability to induce epigenetic modifications, since it is 
beyond the scope of this review. Moreover, we will not discuss exhaustively isolated heart studies, 
because systemic effects cannot be addressed with this model, and they are poorly predictive of in vivo 
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effects, due to metabolic transformation of compounds. For a better understanding, we divided the 
review in the different classes of polyphenols, i.e. flavonoids, stilbenes, phenolic acids and lignans as 
introduced in Figure 2 and for each class, we discuss the effects described for the most representative 
compounds studied in vitro, in vivo and in human trials.  
2. Flavonoids 
2.1. Flavonols 
Flavonols are one of the classes of polyphenols that are widely distributed in plants, and are present 
usually as diverse glucosides, in considerable amounts in onions, apples, cider, grapes, wine and tea. 
They derive from 3-hydroxyflavone, and the simplest flavonol, quercetin, is the most abundant in plants 
and the best studied flavonol in human health [21]. Quercetin cardioprotective properties were 
extensively studied in cellular, animal and even in humans (Table 1). 
Flavonols interfere with a large number of biochemical signaling pathways and, therefore, physiological 
and pathological processes. There is solid evidence that, in vitro, quercetin and related flavonols exert 
endothelium-independent vasodilator effects, protective effect on nitric oxide and endothelial function 
under conditions of oxidative stress, anti-platelet aggregation effects, inhibition of low density 
lipoprotein (LDL) oxidation, reduction of adhesion molecules and other inflammatory markers [21]. 
Plasma isolated from animals, submitted to a widely accepted non-lethal mechanical trauma, was used 
to induce stress in H9c2 cells, a rat cardiomyoblast cell line. Pretreatment with quercetin (20 μM; 24 h 
before trauma, plasma addition) significantly attenuated trauma-induced viability decrease, tumor 
necrosis factor alpha (TNF-α) increase, reactive oxygen species (ROS) overproduction and [Ca2+]i 
overload in H9c2 cardiomyocytes [22]. Another study showed that pretreatment with quercetin before 
I/R could increase H9c2 cells survival. Quercetin significantly alleviated I/R-induced phosphorylation 
of c-Jun N-terminal kinases (JNK) and p38, which further increased B-cell lymphoma 2 (BCL-2) 
expression and inhibited the activation of Bcl-2–associated X (BAX) and caspase-3 [23]. 
One suggested marker for heart diseases in patients with chronic isolated mitral regurgitation and 
ejection fraction >60% is the increased activity of xanthine/xanthine oxidase (X/XO) [24] and it has 
been suggested that some polyphenols exhibit cardioprotection via an effect on X/XO. Thus, to 
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understand the mechanisms underlying cardioprotective effect of quercetin, the expression levels of 
stress-responsive proteins were studied in X/XO-induced toxicity model of H9c2 cardiomyocytes. 
Pretreatment with quercetin (0.1-10 μg/ml; 24 h) enhanced viability and inhibited ROS generation in a 
12h exposure to a free radical generating system X/XO. Moreover, X/XO increased the phosphorylation 
of downstream substrate of p38, mitogen-activated protein kinase-activated protein kinase 2 (MAPK-
APK-2), p44/42-MAPK (Erk1/2) and cleaved caspase-3 but inhibited the levels of phosphorylated c-Jun 
and heat shock protein 27 (HSP27). Pretreatment with quercetin attenuated the phosphorylation of 
MAPK-APK-2 and cleaved caspase-3 in X/XO-exposed cells [25]. 
Quercetin plays also a role in the inhibition of angiotensin II-induced H9c2 cells hypertrophy by 
enhancing peroxisome proliferator-activated receptor gamma (PPAR-γ) expression and suppressing 
activator protein 1 (AP-1) transcription factor activity [26]. The quercetin’s anti-hypertrophic effect has 
been confirmed in neonatal cardiomyocytes by modulation of protein kinase C (PKC) and tyrosine 
protein kinase  activities [27].  
In parallel, quercetin protected also primary cultures of rat cardiomyocytes and H9c2 cells against the 
anticancer agents doxorubicin (DOX) and daunorubicin, well-known to induce acute and long-term 
cardiotoxicity [28-31].  
When administered in a pure form in rats, quercetin limited cardiac hypertrophy and prevented cardiac 
dysfunction and hypertension in several rat models of transverse aortic constriction (TAC) and models 
of hypertension [32-35]. Moreover, one week after TAC and following intragastrical administration for 
6 weeks, the effects of quercetin and the flavanol epigallocatechin-3-gallate (EGCG, see below) were 
compared individually to those of three drugs, namely AT1 receptor blocker losartan, angiotensin I 
converting enzyme (ACE) inhibitor, captopril and beta receptor blocker, carvedilol, for protection 
against abdominal aortic constriction, a recognized model of pressure overload-induced cardiac 
hypertrophy [36]. In this model, malondialdehyde contents progressively increased, while superoxide 
dismutase (SOD) activities decreased. Cardiomyocyte apoptosis, telomere attrition, modulation of p53, 
c-MYC and of the antiapoptotic protein BCL-2 were also evaluated. Interestingly, all compounds 
reduced cardiac hypertrophy and cardiomyocytes apoptosis, but they had different effects on apoptotic-
related proteins BCL-2, p53 and c-MYC, known to promote cell proliferation and cell death when 
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overexpressed [37]. EGCG, quercetin and carvedilol promoted the reduction of malondialdehyde 
(MDA) contents and resumption of SOD activities. Moreover, these 3 compounds could prevent 
telomere attrition and telomere repeat-binding factor 2 (TRF2) loss remarkably, whereas compounds 
such as captopril and losartan had no effect on oxidative stress and telomere [36]. At the molecular level, 
quercetin mediates a down regulation of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, leading to a decrease in superoxide generation and an increase in endothelial nitric oxide 
synthase (eNOS) activity [38]. This might explain, at least in part, how quercetin prevents endothelium 
dysfunction in hypertensive rats [8] and cardiotoxicity in adryamycin treated mice [39].  
A significant amount of clinical studies has investigated the acute and chronic effects of the flavonol 
quercetin or quercetin-3-O-glucoside, with mixed results. A recent meta-analysis investigating the 
effects of quercetin on BP included 7 trials with a total of 587 patients [40]. Significant reductions in 
systolic BP (SBP, -3.04 mm Hg) and diastolic BP (DBP, -2.63 mm Hg) were found after 
supplementation with quercetin. Doses of quercetin equal or higher to 500 mg/day significantly decrease 
SBP and DBP (-4.45 mm Hg, and -2.98 mm Hg, respectively), whereas no significant effects were 
shown for doses lower than 500 mg/day. Another meta-analysis of 5 RCT with 442 subjects [41], 
showed no significant effects on quercetin supplementation on plasma LDL-C, HDL-C or triglycerides 
with a small significant effect in total cholesterol (3.13 mg/dL). At doses higher or equal to 500 mg 
quercetin/ day, significant increase in total cholesterol (3.57 mg/dL) and decrease on triglycerides (-
24.54 mg/dL) was found. Finally, several studies have investigated the effects of quercetin on 
endothelial function with conflicting results. Two recent studies investigating the effects of quercetin-
3-O-glucoside on BP and endothelial function showed no acute effects of 0-400 mg of quercetin-3-O-
glucoside [42] or chronic effects of daily consumption of 160 mg for 4 weeks [43]. Studies investigating 
the effects of quercetin supplementation on endothelial function also failed to show an effect, either 
acute (1095 mg of quercetin) [44] or after 8 weeks supplementation of 150 mg/ day of quercetin [45].  
Other common flavonols include kaempferol, myricetin, isorhamnetin, tamarixetin, morin and fisetin 
(for review :[21]) and as quercetin, whether these compounds effects have been characterized in vitro, 





Flavones are potent molecules mainly found in cereals and herbs. Pure flavones have been evaluated for 
their pharmacological effects on cardiac cell including H9c2 cells, neonatal rat ventricular 
cardiomyocytes or atrial cells. Whether many of them exert , anti-inflammatory, anti-apoptotic activities 
and protect from oxidative stress, many others also show a ion channel modulatory activity or anti 
hypertrophic activity, which may be particularly important in terms of cardiac function [46-50]. 
Reportedly, dietary flavones exert direct vasorelaxing activities [51, 52], but studies evaluating the 
activity of pure flavones are scarce. Apigenin, acacetin and scutellarin are 3 examples of the most studied 
flavones (Table 2) 
Apigenin is described to reduce the inflammatory process induced by liptoteichoic acid in rat 
cardiomyoblast cells [53]. In rats apigenin (50 and 75 mg/kg/day; i.p. for 14 days and ISO (100 mg/kg, 
s.c.) on 13th and 14th days for initiation of cardiotoxicity), attenuated cardiac damages following β-
receptor-stimulated myocardial injury. Apigenin induced protection was associated with effects on 
antioxidant classical markers, i.e. creatine kinase-MB isoenzyme, glutathione, superoxide dismutase and 
catalase and malondialdehyde levels [54].  
Acacetin revealed to be an atrium-selective agent, effectively diminishing atrial fibrillation in 
anesthetized dogs [55]. Moreover the authors also demonstrate that acacetin selectively inhibits human 
atrial repolarization potassium currents [55]. 
An interesting flavone is scutellarin, which is used in traditional Chinese medicine for the treatment of 
various conditions including cardiovascular diseases. Among various activities (Table 2), scutellarin 
could influence positively vascular health via an effect on inflammation in human endothelial cells 
(ECV304 cells) [56]. However, all the mechanistic aspects of its bioabsorption and metabolism in 




Monomeric flavanols, such as catechin, epicatechin, epigallocatechin, gallocatechin, and their gallate 
derivatives, and their polymerization products (proanthocyanidins), can be found in cocoa powder, 
chocolate, teas, and grapes[58]. 
Flavanols promote cardiomyocyte survival in vitro and block cell death in oxidative stress conditions, 
being these effects well described for EGCG, catechin and epicathechin (Table 3). Moreover, some 
beneficial effects would be mediated by action on the contractile machinery, voltage-gated channels, 
Ca2+ homeostasis and cell-to-cell communication (Table 3). 
The main bioactive compounds found in green tea are epicatechins. Among them, EGCG is the most 
described and characterized compound. In rat neonatal ventricular cardiomyocytes (RNVC), oxidative 
stress was induced by lead treatment, causing a decrease in SOD and catalase activities, along with 
increased intracellular levels of hydroxyl radical, anion superoxide and hydrogen peroxide. These 
features were reversed by co-treatment with EGCG, indicating its biological cytoprotective property 
[59]. Likewise, hydrogen peroxide-induced oxidative stress in H9c2 cardiomyocytes promotes apoptosis 
assessed by chromatin condensation, DNA fragmentation and increased expression of p53 and p21, 
telomere length shortening and the decrease of protein expression of Trf2, while pre-treatment with 
EGCG for 24h inhibited telomere-dependent apoptotic pathway induced by hydrogen peroxide [60]. 
Hydrogen peroxide also alters the expression of adherens and gap junction proteins increasing 
intracellular ROS and Ca2+ levels [61]. These effects were attenuated by pre-treatment with EGCG. 
Interestingly, proteomic studies demonstrated that EGCG has multiple cellular targets and binds to the 
67kDa laminin receptor, caveolin-1 and -3, β-actin, myosin 9 and vimentin. Caveolin would serve as a 
membrane raft that may help mediate cardioprotective EGCG transmembrane signaling [61]. Moreover, 
in a high glucose model of arrhythmia in diabetic hearts, ECGC reverted the low levels of connexin 43 
expression in a p38 MAPK-dependent manner in RNVC [62]. In addition, I/R is known to trigger 
oxidative stress and massive cell death during the reperfusion phase. In various cellular models, EGCG 
proved to have anti-apoptotic properties via the activation of phosphoinositide 3-kinase/protein kinase-
B (PI3K/Akt )pathway [63] or via the phosphorylation of signal transducer and activator of transcription 
1 (Stat1), known lays a critical role in the induction of cardiomyocyte apoptosis [64]. Nevertheless, 
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depending on the dose, micromolar vs nonamolar range, EGCG can become toxic by acting on ATP-
sensitive potassium (KATP) channels [65]. 
EGCG’s beneficial role is not limited to apoptosis inhibition, this compound also modulates Ca2+ 
transients and cardiomyocyte beating. In primary cultures of rat cardiomyocytes, DOX decreased cell 
beating and Ca2+ transients, i.e. the rapid increase of Ca2+ in the cell, which peaks and gradually 
decreases during the cardiac action potential. EGCG increased the amplitude of electrical and caffeine-
induced Ca2+ transients in DOX-treated cardiomyocytes, indicating that EGCG may limit the DOX-
induced Ca2+ depletion in the sarcoplasmic reticulum [66]. In another study using EGCG at the 
nanomolar concentration, similar to the circulating dose in human plasma, Feng and colleagues have 
demonstrated that EGCG increases contractibility of murine cardiomyocytes by increasing electrical-
induced Ca2+ transients, content of Ca2+ in sarcoplasmic reticulum and probability of opening of the 
ryanodine receptor [67].  
Catechin and proanthocyanidin B4 are two flavanols found in grape seeds, which prevent DOX-induced 
cardiomyocytes death by decreasing ROS generation and limiting DNA fragmentation [68]. Likewise, 
as other grape polyphenols such as quercetin and resveratrol , catechin could be cardioprotective by 
inhibiting cardiac voltage-gated sodium channels activity in left ventricular rat myocytes and therefore, 
preventing cardiac arrythmias [69]. The IC50 of the 3 compounds were 19.4 μM, 77.3 μM and 76.8 μM, 
respectively. Intriguingly, the absence of blocking effect of N-acetylcysteine on this channel suggests 
that the compounds act independently of their cytoprotective effects [69]. 
Theaflavin-3,3'-digallate (TF3) present in black tea limited cell death induced by hydrogen peroxide in 
RNVC, as observed for EGCG [70]. Although TF3 activates extracellular signal-regulated kinase 
(ERK) 1/2, Akt and p38 mitogen-activated protein kinase, whenever these kinases are inhibited, TF3 is 
still able to promote cell survival and prevent intracellular ROS accumulation. Thus, kinases are not 
essential for TF3-mediated cardioprotection [70]. In the same cell model and again in comparison to 
EGCG, methyl gallate, a methyl ester of gallic acid, inhibits apoptosis by decreasing intracellular ROS 




Epicatechin is considered an important factor associated to the cardiovascular beneficial effects of 
flavanol-rich foods [72]. Pharmacological studies have found that epicathechin exhibits protective 
effects on oxidative stress injury, myocardial ischemia reperfusion injury and permanent coronary 
occlusion[73-75]. Epicathechin treatment also improved mitochondrial structure in enhanced cardiac 
function in patients with heart failure. However, is fairly unknown whether epicathechin has a direct 
effect on cardiac hypertrophy and the mechanism underlying its anti-hypertrophic role remains poorly 
clarified. A recent study with neonatal mouse cardiomyocytes shown that epicatechin significantly 
inhibited Ang II-induced increase of cardiomyocyte size by activating the specificity protein 1/Sirtuin 1 
(SP1/SIRT1) signalling pathway [76]. Moreover, 1 mg/kg body weight/day epicathechin significantly 
inhibited mouse cardiac hypertrophy induced by Ang II, which could be eliminated by SP1 inhibition in 
vivo [76].   
The flavanols proved their ability to prevent cardiac damages also in several rodents models, at least by 
increasing antioxidant capacity in the heart and other organs [77, 78] (Table 3). For example, two weeks 
of administration of epicatechin in drinking water (100 mg/kg/day) prevented BP increase in young 
spontaneously hypertensive rats and thus, diminished locomotor activity. Underlying mechanisms 
involved an increase in iNOS activity and a reduction in superoxide production in left ventricle and aorta 
[77]. When administrated seven days before isoproterenol (100mg/kg, s.c.), EGCG (15mg/kg, i.p.) 
prevented cardiac damages by maintaining the balance of anti-apoptotic / pro-apoptotic signaling 
proteins in the mitochondrial pathway of cell death, limiting oxidative stress inflammation, and 
protecting DNA integrity [78].   
Several meta-analysis have confirmed that cocoa flavanol consumption can improve endothelial 
function and decrease BP. A couple of studies have investigated the effects of the main flavanol 
monomer present in cocoa, epicatechin, which is believed to be responsible for the cardiovascular health 
benefits of cocoa intake. Consumption of 1-2 mg of (-)-epicatechin/kg body weight (BW) was shown to 
acutely improve endothelial function in healthy individuals [72, 79]. In contrast, a recent study by Dower 
et al. did not detect statistically significant long-term changes in flow-mediated vasodilation (FMD) or 
BP after 4 weeks supplementation with 100 mg of (−)-epicatechin per day [80]. Although more studies 
14 
 
are needed to confirm these contrasting findings, it may be that investigations using a purified dietary 
constituent do not fully mimic the effects or effect sizes observed when the same constituent is consumed 
in its native food/food matrix.  In a very recent study, Sansone et al. [81] reported that cocoa 
methylxanthines (theobromine and caffeine) enhanced the vascular effects exerted by cocoa flavanols 
and also improve their bioavailability. This shows that synergistic effects between polyphenols and other 
dietary compounds exist, which may explain the different effects observed when pure compounds and 
polyphenol rich foods or extracts were tested. Synergistic effects between cocoa flavanols and dietary 
nitrate, another food bioactive present in vegetables, have also been shown at dietary achievable amounts 
[82]. 
 
2.4 Flavanones  
Flavanones are the major class of polyphenols present in Citrus fruit, they include hesperidin, 
naringenin, eriodictyol among others, and their respective glycosides [83]. Naringenin and its respective 
glucoside, naringenin-7-O-glucoside are the most well studied in cell culture of cardiomyocytes (Table 
4). Naringenin has been reported to exhibit cardioprotective effects, namely, anti-inflammatory, 
hypolipidemic, and anti-atherogenic properties [84]. The treatment of H9c2 cells with pure naringenin 
was shown to be effective against I/R injury via attenuating endoplasmic reticulum (ER) stress or ER 
stress-mediated apoptosis. Naringenin treatment restored cell viability, cell morphology, normalized 
BCL-2, BAX and caspase 3 in I/R-treated H9c2 cells. Likewise, the protective effect of naringenin 
against I/R injury is due to inhibition of ER stress-mediated apoptosis, which potentially involves 
activation of transcription factor 6 (ATF6), inositol-requiring enzyme-1α (IRE1α) and phospho-
extracellular regulated protein kinases (PERK) [85]. Thus, pretreatment of H9c2 cells with naringenin 
promoted the reduction of ER-mediated apoptotic cell death and lipid peroxidation, and showed 
increased level of reduced glutathione when these cells were submitted to an oxidative insult such as 
H2O2. In addition, gene expression studies revealed that naringenin upregulated the transcription of Akt, 
nuclear factor erythroid-derived 2-like 2 (Nrf2) and its target genes, and downregulated nuclear factor-
kappa B (NF-κB) and caspase 3 expression. This study suggests that improvement of Nrf2 signaling via 
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naringenin supplementation would be a rational approach to facilitate ROS detoxification by augmenting 
both expression and activity of phase II detoxification enzymes, which in turn alleviate cardiac 
complications [86].  
In a very recent study, in a cellular model of senescent myocardial cells, it was observed that naringenin 
reduce relevant cellular senescence markers (X-gal staining, cell cycle regulator levels, and the 
percentage of cell cycle-arrested cells). Moreover naringenin modulate cardiac markers of aging-
induced damage (e.g. ROS, mitochondrial metabolic activity, mitochondrial calcium buffer capacity, 
and estrogenic signaling functions). Overall the authors suggest that naringenin has antiaging effects on 
myocardial cells [87]. 
Some studies suggest that naringenin and naringenin-7-O-glucoside could prevent cardiomyocytes from 
DOX-induced toxicity by their property of stabilizing the cell membrane and reducing ROS generation, 
promoting the induction of endogenous antioxidant enzymes via phosphorylation of ERK1/2 and nuclear 
translocation of Nrf2.  These effects could underlie the use of these flavanones as therapeutic agents for 
treating or preventing cardiomyopathy associated with DOX [30, 88-90]. 
In mice naringenin is able to exert a protective effect against cardiac hypertrophy induced by pressure 
overload. Diet supplementation with naringenin attenuated cardiac hypertrophy and interstitial fibrosis, 
in addition to improving left ventricular function. The cardioprotective effect exerted by naringenin was 
associated with the inhibition of PI3K/Akt, ERK and JNK signaling pathways[91]. 
Liu et al. showed that naringenin can improve cardiac and renal function in a rat model of cardiorenal 
syndrome, a complex disorder in which each organ has a deleterious effect on the other. Indeed, 
naringenin (25 mg/kg/day or 50 mg/kg/day, 4 weeks, oral gavage) attenuated cardiac remodeling and 
cardiac dysfunction, decreased lipid profiles, inhibited cardiac inflammation and reduced oxidative 
stress. Nrf2 and/or catalytic subunit of glutamylcysteine ligase-regulated glutathione (GSH) synthesis 
contributed to narigenin-induced protective effects [92].  
Hesperidin found in citrus fruits upon ingestion releases its aglycone, hesperetin that have been studied 
for cardioprotective activity in in vitro systems (Table 4). The post treatment of rat cardiomyocytes 
submitted to H/R injury with hesperitin inhibited apoptosis by elevating Bcl-2 expression and decreasing 
Bax and and cleaved caspase-3 expression levels. It was observed that this protective effect was 
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mediated through the activation of PI3K/Akt signalling pathway [93]. Another evidence of hesperetin 
anti-apoptotic effect was observed in lipopolysaccharide (LPS)-induced H9C2 cells via the JNK/Bax 
signalling pathway. Hesperitin has a mitochondria-dependent anti-apoptosis effects in these cells by 
downregulation of Bax and upregulation of Bcl-2 concomitant with the attenuation of JNK 
phosphorylation [94].  
In rats hesperidin (50 mg/kg/day HP, 14 days, oral gavage) was found to protect rat cardiac function 
treated by the anticancer drug cisplatin, [95]. With a shorter treatment at a higher dose, hesperidin 
treatment (200 mg/kg hesperidin/rat, 3 days, oral gavage) attenuates myocardial I/R injury by 
suppressing myocardial apoptosis, the inflammatory response and oxidative stress via PI3K/Akt 
pathway activation and HMGB1 (high–mobility group box 1) inhibition in rats [96]. In a rat model of 
left ventricular remodelling,  induced by a permanent left anterior descending coronary artery (LAD) 
occlusion,  cardiac dysfunction, myocyte apoptosis and inflammation were significantly attenuated by 
hesperidin (30 mg/kg/day, oral gavage), via an inhibition of caspase-3 activity, myeloperoxidase 
expression, α-smooth muscle actin expression, and matrix metalloproteinase-2 activity. In the same 
study, hesperidin prevented also myocardial infarction-induced ventricular dysfunction and structural 
remodelling of myocardium [97]. Finally, hesperidin (100 mg/kg/day, oral gavage) proved also to exert 
beneficial cardioprotective activity in a cardiac I/R injury in diabetic rats when performed a  LAD 
occlusion an effect mediated by  PPAR-γ pathway [98].  
To date, only 4 studies have investigated the effects of pure hesperidin on vascular function in humans 
(Table 4). Consumption of 500 mg of pure hesperidin per day for 3 weeks, resulted in significant 
improvements in endothelial function measured as FMD in subjects with the metabolic syndrome, 
through NO production [99]. Also, both orange juice and hesperidin capsules (containing both 292 mg 
of hesperidin) significantly improve acetylcholine-mediated vasodilation 6 h after ingestion on healthy 
overweight men, and decreased DBP after 4 weeks daily consumption [100]. In contrast, two recent 
studies have reported no improvements in CVD markers after hesperidin supplementation.  An acute 
study in healthy individuals showed no effects on FMD, BP, or arterial stiffness when 320 mg of 
hesperidin was given as a pure compound or as an orange juice [101]. In a 6 week study in overweight 




2.5 Isoflavones  
Isoflavones have gained considerable attention for their potential role in improving risk factors for 
cardiovascular disease. Experimental models have used cardiac cells, live animals and were also tested 
in humans (Table 5). Genistein is an isoflavone present in several plants, including soya, lupin and fava 
beans. This isoflavone is widely described as a modulator of ionic channels, acting by direct binding or 
by interfering with key modulatory phosphorylation processes as a tyrosine kinase (TK) inhibitor [103]. 
Regarding its effects on the cardiovascular system, this compound is able to modify cardiomyocytes 
function, particularly by modifying Ca2+ signalling and homeostasis via effects on multiple targets. In 
guinea-pig myocytes, genistein directly interacts with L-type Ca2+ channel, reducing Ca2+ currents, and 
consequently Ca2+ influx [104]. However, genistein can also stimulate Ca2+ influx in cardiomyocytes by 
direct interacting with transient receptor potential cation channel 5,TRPC5 [104]. On the other hand, by 
acting on the Na+/Ca2+ exchanger, this isoflavone impairs its ability to extrude Ca2+. Genistein also 
increases sarcoplasmic reticulum Ca2+ load, which may be a cellular compensatory response to Na+/Ca2+ 
exchanger modifications. Accordingly, genistein increases intracellular Ca2+ levels, Ca2+ transients and 
myofilament sensitivity to Ca2+. Thus, genistein exposure enhances cardiomyocytes contractility [105]. 
The inward rectifying K+ current contributes to the terminal phase of action potential repolarization and 
to maintain the resting membrane potential in cardiomyocytes. Exposure to genistein inhibits inward 
rectifying K+ current, which can also lead to an abnormal function of cardiomyocytes [106]. 
cAMP-dependent chloride currents are critical in cardiomyocytes excitation-contraction coupling. It has 
been shown that cAMP-regulated cystic fibrosis transmembrane regulator (CFTR) Cl- currents can be 
induced in guinea-pigs cardiomyocytes by genistein application, in a TK inhibition-independent way 
that requires prior PKA activation [107]. Furthermore, in the presence of a β-adrenergic agonist, 
genistein increased (i) the sensitivity of cAMP-regulated CFTR Cl-, (ii) cAMP-regulated delayed 
rectifier K+ current and (iii) L-type Ca2+ currents [107]. 
Several authors also described a cytoprotective effect of genistein against cell death. Genistein has an 
antiapoptotic activity against deleterious cardiac effects of arsenic trioxide, an anticancer agent used for 
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acute promyelocytic leukemia treatment. Intravenous injection of genistein in rat rescued long QT 
syndrome and dose-dependently improved arsenic trioxide-induced impairment of cardiac function. 
Moreover, pretreatment of RNVC with genistein before arsenic trioxide prevented mitochondrial 
membrane potential loss and inhibits JNK, p38-MAPK and caspase-3 activation [108]. Following an I/R 
injury, genistein is able to increase antiapoptotic BCL-2 expression and reduce BAX expression and 
caspase 3 activation. Likewise, genistein downregulates the expression levels of ER stress proteins, 
increasing cell viability of H9c2 cardiomyocytes [109]. Also, genistein effectively reverses glucose 
toxicity-induced mechanical malfunction in rat primary ventricular myocytes, a model that simulates 
diabetic cardiomyopathy [109]. In isolated guinea pig left ventricular papillary muscles, genistein 
stimulates myocardial contractility by inhibition of TK pathway and PI3K activity, but independently of 
the activation of β-adrenoceptor, the Na+–Ca2+ reverse exchange and the estrogen receptor [110]. 
Puerarin is an isoflavone derived from Pueraria lobata roots, commonly found as a Chinese herb 
medicine. Several studies showed that treatment of ventricular neonatal cardiomyocytes with puerarin 
decreases angiotensin II-induced ROS production. Likewise, puerarin supresses the activation of 
ERK1/2, p38 and NF-κB signalling pathways, limiting cardiac hypertrophy caused by angiotensin II 
[111]. It has been suggested that the anti-hypertrophic effect of puerarin occurs due to blocking of Rac1-
dependent NADPH oxidase activation and AP-1 signalling pathway [112]. In addition, puerarin is able 
to block Na2+ currents in cardiomyocytes. Actually, results indicate that puerarin can block the 
inactivation state of the Na2+ channel and delay the recovery of the channel from its inactive state, 
suggesting a putative application as an antiarrhythmic agent [113]. Moreover, by upregulating BCL2-
associated athanogene 3 (BAG3), puerarin enhances autophagy in RNVC, having and antiapoptotic 
effect against anoxia/reoxygenation injury [114].  
Other isoflavones have been revealed as cardioprotective, for instance formononetin is the major 
isoflavone found in Radix Astragali, a Chinese medicinal plant widely used to treat cardiovascular 
diseases. It has been described that this compound reduces ROS formation, as well as mitochondrial 
damage, increasing cell viability of rat cardiomyocyte H9c2 cell line, after oxygen-glucose deprivation 
and reoxygenation [115]. Thus, by activating Akt and increasing glycogen synthase kinase-3β (GSK-
3β) phosphorylation, formononetin enhances the interaction between phospho-GSK-3β and adenine 
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nucleotide translocase, the mitochondrial permeability transition pore (mPTP) major component, which 
decreases mPTP opening and prevents apoptosis [115]. 
In a rat model of myocardial I/R injury genistein was tested for cardiovascular protection and inhibition 
of the inflammatory response. It was observed that it lowers myocardial necrosis and myocardial 
myeloperoxidase activity activity in the area-at-risk and in the necrotic area, decreases creatinine 
phosphokinase activity activity, increases myocardial contractility, decreases ventricular arrhythmias, 
reduces serum and macrophages levels of TNF- and blunts cardiac intercellular adhesion molecule-1 
(ICAM-1) expression in the injured myocardium [116]. Likewise, in vitro, genistein addition to 
peritoneal macrophages collected from untreated rats subjected to myocardial I/R injury (i.e. sham rats) 
significantly reduced TNF- production, suggesting that genistein limits the inflammatory response and 
protects against myocardial I/R injury [116]. Moreover, genistein ameliorates pressure overload-induced 
cardiac dysfunction and interstitial fibrosis in mice [117]. In line with these observations, beneficial 
effects of genistin, a genistein glucoside, in rat myocardial I/R injury might involve reduction on 
oxidative stress and anti-inflammatory effects via suppression of the P2X purinoceptor 7 (P2X7)/NF-
𝜅B axis [118].   
Puerarin, when administrated orally at 100 mg/kg for 15 days, inhibits angiotensin II-induced cardiac 
hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways in mice. Moreover, puerarin 
significantly suppressed angiotensin II-induced increases in atrial natriuretic peptide (ANP), B-type 
natriuretic peptide (BNP) and β -myosin heavy chain (β-MHC) expression in the left ventricles in vivo 
[111]. Protective effects were confirmed in vitro by pretreatment of RNVC by 50, 100, and 200 μmol/L 
of puerarin for two hours: a decrease in ROS production, protein synthesis and cell death were observed. 
Furthermore, puerarin significantly suppressed Ang II-induced activation of ERK1/2, p38 and the NF-
κB pathway proteins and the expression of ANP and β-MHC in cardiomyocytes. Next, it was proposed 
that puerarin effects could be mediated by Mir-15b/195 expression and suppressing non-canonical 
transforming growth factor beta (TGF) signal pathway [119]. Recently, puerarin effects were extended 
to endothelial cells in angiotensin II-induced hypertensive rats [120]. Compared with control rats, 
angiotensin II-infused rats exhibited an impaired endothelium-dependent relaxation to acetylcholine 
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with reduction in the protein expression of phosphor-eNOS at Ser 1177 and an increase in the expression 
of gp91phox (85%), p22phox (113%), TGF1 (145%) and vascular cell adhesion molecule 1 (VCAM-
1)(82%). Puerarin (100 mg/kg/day, IP once a day for 10 days) improved endothelium-dependent 
relaxation and reversed the changes in angiotensin II-induced protein expression of above molecules 
[120]. 
A meta-analysis on 11 human trials investigating the effects of isoflavones on BP concluded that soy 
isoflavone are effective in reducing both SBP and DBP in hypertensive subjects, but not in normotensive 
individuals [121]. Another meta-analysis of RCTs showed that isolated isoflavone consumption 
improved endothelial function [122]. Two meta-analysis also confirmed the blood cholesterol lowering 
effects of isoflavones [123, 124], although whether the effect is due to isoflavones or to soy protein is 
still controversial. Indeed, a more recent meta-analysis found no effects of isoflavones on blood lipids 
in hypercholesterolemic patients [125]. Not included in this meta-analysis, and important because of its 
length, is a 1-year RCT in post-menopausal women with the metabolic syndrome that showed reductions 
in SBP and DBP, improvements in blood lipids, fasting glucose and HOMA-IR (Homeostatic Model 
Assessment for Insulin Resistance) after supplementation with genistein (54 mg/day) [126]. Another 1 
year study where cocoa flavanols and isoflavones (850 mg and 100 mg per day, respectively) were 
consumed daily by postmenopausal women with type 2 diabetes reported improvements in blood lipids, 
insulin resistance and insulin sensitivity [127], although no changes in BP or endothelial function were 
observed [128]. 
 
2.6 Anthocyanins  
Anthocyanins are one of the most widely distributed colorants in fruits and vegetables. The main 
anthocyanins are delphinidin, cyanidin, pelargonidin, malvinidin, peonidin, and petunidin (for review: 
[129]). There are some studies indicating cardioprotective activities to anthocyanins enriched extracts 
but very few studies with pure anthocyanins (Table 6). Six anthocyanidins (aglycones) and seven 
anthocyanins (glucosides) effects against DOX-induced cardiotoxicity were investigated in H9c2 
cardiomyocytes [130]. Cyanidin and delphinidin were the most potent in protecting against cytotoxicity, 
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as well as reducing the lipid peroxidation induced by DOX treatment. In contrast, seven anthocyanins 
showed little effect in cytoprotection and lipid peroxidation, although they markedly blocked 
intracellular ROS generation [130]. However, in the same cells subjected to simulated I/R and to tert-
butyl hydroperoxide, cyanidin shows only a slightly protection and delphinidin no effect at 5 μM. 
Importantly, higher doses were cytotoxic [130].  
Anthocyanins cardioprotective activities have been largely demonstrated in animal models and humans 
[131], but the number of studies based on pure anthocyanins delivery is limited. However, it has been 
shown that anthocycanins such as delphinidin 3-O-β-rutinoside , cyanidin 3-O-β-rutinoside , delphinidin 
3-O-β-glucoside, and cyanidin 3-O-β-glucoside  are well absorbed and distributed to the blood in their 
intact form in rat and humans [132].  
In addition to cytoprotective activity towards oxidative stress  and anti-inflammatory activities, it 
emerged recently that anthocyanins can also target intracellular pathways and notably apoptosis and 
mitochondria at the level of respiration and of pro-apoptotic cytochrome c release (for review : [129]). 
For instance, it has been proposed that delphinidin could target Stat1 on the basis of ex vivo I/R 
experiments [133]. In addition, cyanidin 3-glucoside from purple corn was shown to ameliorate DOX-
induced cardiotoxicity by a histological comparative study in mice [134]. More precisely, the effects of 
delphinidin 3-O-β-glucoside, cyanidin 3-O-β-glucoside and pelargonidin 3-O-glucoside  on the activity 
of complex I of the mitochondrial respiratory chain were studied in mitochondria isolated from normal 
rat hearts and rat hearts subjected to ischemia [135]. Delphinidin 3-O-β-glucoside and cyanidin 3-O-β-
glucoside, but not pelargonidin 3-O-glucoside, improved state 3 respiration and ATP synthesis in 
mitochondria after ischemia, suggesting that certain anthocyanins can act as electron acceptors at 
complex I and bypass ischemia-induced inhibition, resulting in increased ATP production after 
ischemia. For the first time this study revealed that pure anthocyanins could directly regulate 
mitochondrial energetic metabolism [135]. 
However, anthocyanins can also become toxic depending on their dose. For example, bilberry 
anthocyanins (0.01–1 mg/L) significantly attenuated the extent of I/R injury in isolated heart as 
evidenced by decreasing the release rate of lactate dehydrogenase, increasing the post-ischemic coronary 
flow, and by decreasing the incidence and duration of reperfusion arrhythmias. High concentrations (5–
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50 mg/L) exhibited cardiotoxic activity despite having their radical scavenging and intracellular 
antioxidant capabilities increased in a concentration-dependent manner [136]. 
Few clinical studies with pure anthocyanin capsules have been conducted, mainly in diseased 
populations. Recent meta-analysis highlighted the evidence on the cholesterol-lowering effects of 
anthocyanins and anthocyanin-rich foods in dyslipidemic individuals [137-139]. The effects of pure 
anthocyanins on BP is yet unclear, and a recent meta-analysis of just 6 trials found no evidence of 
beneficial effects [140]. Very few studies have investigated the effects of pure anthocyanins on 
endothelial function, with only one study showing improvements in FMD after acute and 12 week 
consumption of 320 mg of anthocyanins per day in hypercholesterolemics [141]. Although the 
epidemiological and clinical evidence of the cardioprotective effects of berries is accumulating in the 
last few years [16], more studies with pure anthocyanins are needed in order to confirm that anthocyanins 
are indeed the bioactive compounds responsible for the effects.  
 
3. Stilbenes 
Resveratrol  is undoubtedly the pure polyphenol that has attracted more attention and been most 
frequently evaluated for pharmacological and therapeutic implication in cardioprotection [142] (Table 
7). This is due to its postulated role in the so-called “French paradox”, although the presence of 
resveratrol in the human diet is probably almost negligible [143, 144].  
As previously said, cardiac hypertrophy is an adaptive heart response, nevertheless, whenever 
hypertrophy is chronic, there is a higher risk of HF and cell loss. RNVC were used to study whether 
resveratrol prevents hypertrophy and apoptosis induced by isoproterenol, a beta-adrenergic receptor 
agonist. Co-treatment of cardiomyocytes with resveratrol and isoproterenol reverted hypertrophy by 
decreasing cell surface and the expression of ANP that is a biomarker for hypertrophy [145]. 
Furthermore, resveratrol limited apoptosis induced by isoproterenol via partial inhibition of ER stress 
response protein expression, namely 78kDa glucose-regulated protein (GRP78), 94kDa glucose-
regulated protein (GRP94) and CCAAT-enhancer-binding protein homologous protein (CHOP) [145]. 
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In right ventricular rat myocytes, resveratrol treatment inhibits cardiac voltage-gated sodium channels, 
which is another mechanism by which  plays its cardioprotective and antiarrhythmic role [69].  
Cardiac ischemic stroke generates heart lesion and tissue loss in particular during reperfusion phase. A 
protocol of anoxia (3h) and re-oxygenation (2h) was used in RNVC for evaluating the cytoprotective 
and anti-inflammatory role of resveratrol. Whenever, resveratrol is added to the cells immediately after 
re-oxygenation, there is a decrease of cell death, assessed by lactate deshydrogenase release and 
apoptosis assed by caspase-3 activation, concomitantly with a reduction of pro-inflammatory factors, 
namely tumor necrosis factor (TNF-α) and interleukin (IL)-1β [146]. Moreover, resveratrol decreased 
the expression of MiR-34a, which is a miRNA enhancing pro-apoptotic signaling and consequently, 
increasing cell death induced by anoxia/re-oxygenation in H9c2 cells [147]. 
In diabetes-induced cardiomyopathy, there is a significant correlation between hyperglycemia, oxidative 
stress and cardiomyocyte apoptosis. The pre-treatment of RNVC with resveratrol inhibited 
hyperglycemia-induced ROS generation and decreases NADPH oxidase activity, this effect being along 
with inhibition of apoptosis and increase of phosphorylation of AMP-activated protein kinase (AMPK) 
[148]. Furthermore, whenever AMPK is pharmacologically inhibited, there is a reversion of resveratrol 
beneficial effects revealing its essential role [149]. Using H9c2 cell line, resveratrol also reverts 
cardiotoxic effects of hyperglycemia by  stimulating sirtuin 1 (SIRT1) [150]. In contrast, resveratrol 
prevented DOX-induced cell death cardiomyocytes by activating of SIRT1 [151], as well as by 
phosphorylation of AMPK, which in turn prevents apoptosis via AMPK/p53 pathway [152].  
Finally, resveratrol also modulates autophagic pathways which may limit apoptosis. Hydrogen peroxide-
induced cell death was prevented by resveratrol via SIRT1 autophagy activation, involving Beclin 1, 
microtubule-associated protein 1A/1B-light chain 3 (LC3), p62 and lysosome-associated membrane 
protein 2a (LAMP2a)[153]  
Bakuchiol, which is an analog of resveratrol (Table 7) and is found in the seeds of Psoralea corylifolia, 
limits cell death in isolated rat heart and cardiomyocytes challenged by I/R injury in a SIRT1 dependent 
manner [154]. In addition, bakuchiol significantly increased the activities of mitochondrial succinate 
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dehydrogenase, cytochrome c oxidase, and mitochondrial SOD and decreased the production of 
malondialdehyde [154]. Thus, bakuchiol is cardioprotective by targeting mitochondrial function in a 
SIRT-dependent way. Likewise, pterostilbene, which is a natural dimethyl ether derivative of resveratrol 
(Table 7), binds to the pocket of SIRT1 assessed by molecular docking analysis. Furthermore, it prevents 
cardiomyocyte death induced by I/R, upregulates SIRT1 expression, and whenever SIRT1 activity is 
inhibited, pterostilbene-induced cardioprotection is reverted [149]. 
In vivo, resveratrol has multiple effects such as a protective action of vascular walls towards oxidation, 
inflammation, platelet oxidation and thrombus formation [155]. Thus, resveratrol protects against LPS-
induced cardiac dysfunction by enhancing sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity 
through promoting the phospholamban oligomerization, the inhibitor of the Ca2+ pump in the 
sarcoplasmic reticulum [156]. Moreover, iron-overload injury and cardiomyopathy in acquired and 
genetic models is attenuated by resveratrol therapy [157]. Resveratrol can also ameliorate aging-related 
metabolic phenotypes and cardiac function by inhibiting some cyclic nucleotides phosphodiesterases 
(PDE), such as PDE4 [158]. In the heart, PDEs are compartmentalized enzymes that degrade the cAMP 
second messenger into inactive 5’ AMP and are critically involved in pathogenesis of HF [159]. Park et 
al. showed that the metabolic effects of resveratrol in mice result from competitive inhibition of cAMP-
degrading phosphodiesterases, leading to elevated cAMP levels. The resulting activation of exchange 
factor directly activated by cAMP 1 (Epac1), a cAMP effector protein, increases intracellular Ca2+ 
levels and activates the Ca2+/calmodulin-dependent protein kinase kinase β/AMP-activated 
protein kinase (CaMKKβ-AMPK) pathway via phospholipase C and the ryanodine receptor Ca2+-
release channel. As a consequence, resveratrol increased nicotinamide adenine dinucleotide (NAD+) and 
the activity of SIRT1 and then, ameliorate the symptoms of metabolic diseases associated with aging 
[158].  
As a model of diabetic cardiomyopathy, db/db mice were treated with resveratrol (0.3% mixed in chow) 
for 8 weeks. Resveratrol restored cardiac function, reduced cardiomyocyte apoptosis, and ameliorated 
ER stress via an activation of SIRT1 [150]. Unfortunately, it has been shown that the SIRT1 effect is 
not direct in this model, opening a still ongoing debate on the direct resveratrol target (s) [160, 161].  
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Resveratrol could also significantly improve cardiac dysfunction in many models of hypertension via 
effects on inflammation and oxidative stress and a plethora of molecular targets such as SIRT-1, AMPK, 
Nrf2, NF-κB, endothelial nitric oxide synthase  (eNOS) [143]. However, resveratrol could prevent 
cardiac hypertrophy and contractile dysfunction in simulated HR rats, i.e. spontaneously hypertensive 
rats without lowering BP [162]. This effect could be mediated by a reduction in oxidative stress. 
Although the relevance of resveratrol as a beneficial dietary compound is very limited due to its low 
abundance in foods, and it is very unlikely that it will be responsible for the beneficial effects of berries 
and red wine, it has potential as therapeutic agent at pharmacological doses. For example, consumption 
of 150 mg of resveratrol or higher has been shown to reduce systolic BP, but not lower doses [163]. A 
meta-analysis of  7 RCT showed no effects on total cholesterol, HDL-C, LDL-C, and triglycerides, 
regardless of  dose [164], whereas some positive effects were shown on glucose control and insulin 
sensitivity but only in diabetic patients [165]. Consumption of 75 mg of resveratrol daily for 6 weeks 
improved endothelial function in overweight individuals and an acute dose-response was reported in the 
same population [166, 167].      
 
4. Phenolic acids 
Phenolic acids have recently gained substantial attention due to their various biological and 
pharmacological effects, including cardioprotective effects (Table 8) [168]. Among other pure 
polyphenols investigated for its bioactivity, gallic acid is found in many plants and products such as tea 
leaves, grapes, blackberry, and gallnuts. It have been reported cardioprotective properties of gallic acid 
and gallates esters (Table 8) [169]. In RNVC and H9c2 cardiomyoblast cells, gallic acid decreases the 
isoproterenol-induced hypertrophy observed by a reduction of cell size and sarcomere organization. 
Moreover, the expression of the genes for β-myosin heavy chain, ANP and brain natriuretic peptide, 
markers of cardiac hypertrophy were also reduced  [170]. Likewise, gallic acid was described to exhibit 
protective role against advanced-glycation end products (AGEs)-induced oxidative stress in cardiac 
cells. Exposure of cardiac H9c2 cells to AGEs resulted in an increase in ROS and decline in antioxidant 
enzyme levels and an increase in collagen content, an effect reduced by the free radical scavenging 
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activity of gallic acid [170]. This suggests a protective role against AGEs-induced cardiovascular 
complications. In a cardiotoxicity scenario induced by an organophosphate pesticide, gallic acid reveals 
protective properties in the cardiac stress in H9c2 cardiomyocytes by reversing cellular distortion, 
suppressing ROS levels and increasing collagen content [171].  
In rat cardiomyocytes, ellagic acid reduces Ca2+ currents not by direct interaction with Ca2+ channel but 
through modulation of the nitric oxide-guanylate cyclase-cGMP pathways, and this effect could be 
useful in pathological conditions such as hypertension and ischemic heart diseases [172]. Moreover, 
caffeic acid and chlorogenic acid, compounds present in berries extract, are able to limit oxidative stress 
induced by hydrogen peroxide in chick embryo ventricular myocytes [173]. Furthermore, isoproterenol-
induced oxidative stress in HL-1 mouse atrial muscle cell line was reverted by treatment with caffeic 
acid [174]. In RNVC, chlorogenic acid inhibits isoproterenol-induced cardiac hypertrophy by 
attenuating NF-κB signaling pathway and suppressing ROS [175]. Moreover caffeic, chlorogenic and 
rosmarinic acids protected cardiomyocytes against DOX induced oxidative stress [176], at levels 
compared to dexrazoxan, used in the past as an antioxidant during DOX chemotherapy. Protocatechuic 
acid (PCA), a phenolic compound occurring in some food sources like açai palm fruit and mushrooms, 
has been found to possess various biological activities. In a RNVC model of I/R injury, PCA 
significantly inhibited the apoptotic rate and the expression of cleaved caspase-3, and it upregulated the 
expression of phosphorylated Akt therefore conferring cardioprotection [177]. PCA aldehyde, present 
in the root of Salvia miltiorrhiza (Lamiaceae), commonly known as Danshen in China, has been 
described as active against I/R injury [178]. PCA aldehyde administration markedly reduced cellular 
injury induced by simulated I/R in cultured RNVC, by involving the suppression of inflammatory 
response via inhibiting the NF-κB signaling pathway. In vivo, PCA could provide a significant protection 
against myocardial I/R injury through regulation of the inflammatory response, platelet aggregation, and 
cardiomyocyte apoptosis [177]. 
Ferulic acid is present in Chinese medicinal herbs and exhibit pharmacological activities such anti-
inflammatory, platelet aggregation inhibitory, antihypertensive and anti-apoptotic effects [179, 180]. In 
a daunorubicin-induced cardiotoxicity model in H9c2 cells, it was observed cellular protection by this 
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compound from the induced apoptosis through a mechanism that involves the interruption of the ERKs 
signalling pathway [181].  In a scenario of anoxia/reoxygenation injury, where induced intracellular Ca2+ 
overload is an important pathophysiological factor, it was observed that sodium ferulate attenuates this 
increase and improves cell survival in cultured cardiomyocytes through nitric oxide/cGMP-dependent 
protein kinase (cGMP/PKG) signal pathway [182]. 
Salvianolic acid B (SalB) is one of the major bioactive compounds from Salvia miltiorrhiza, whose roots 
are used in Chinese traditional medicine, and presents cardioprotective role against several different 
cardiac stresses and cardiopathies. In neonatal rat cardiomyocytes, angiotensin II-induced hypertrophy 
is reversed by SalB treatment via inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) [183]. 
Furthermore, SalB decreases ROS generation by limiting NADPH oxidase 2 and 4 expression [183]. 
Likewise, exacerbated inflammation can also stimulate cellular stress and death in cardiomyocytes. 
Thus, in neonatal rat cardiomyocytes, LPS promotes inflammation as shown by TNF-α assessment and 
cell death measured by lactate deshydrogenase (LDH) release. Whenever cardiomyocytes are pre-
treated with SalB, there is reversion of both effects by the activation of toll-like receptor 4 (TLR4)-NF-
κB-TNF-α pathway [184]. 
Prevention of autophagic process is also involved in SalB-induced cardioprotection. Indeed, in RNVC, 
3h of starvation stimulates autophagy detected by increased levels of LC3II and apoptosis as shown by 
higher levels of caspase-8 and decrease in ATP concentration. Interestingly, co-treatment with SalB 
reverted autophagy and apoptosis, SalB acting on the crosstalk between both signaling pathways [185]. 
Likewise, SalB also limits autophagy and cell death in response to I/R by modulation of microRNA 
(miR) in a model of murine cardiomyocytes [186]. Actually miRs are endogenous regulators of gene 
expression and can play key roles in cell signaling. I/R promote the activation of autophagy and 
apoptosis and down-regulates miR-30a expression. In contrast, SalB reverts the suppression of miR-30a 
expression and limits autophagy and apoptosis in a PI3K/Akt pathway dependent manner [186]. 
Furthermore, whenever miR-30a is knocked down, SalB loses its cardioprotective role [186]. 
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SalB also appears as an anti-apoptotic agent against cardiotoxicity induced by the anti-neoplastic drug 
arsenic trioxide. Indeed, SalB activates PI3K/Akt pathway and increases Bcl-2 and Bcl-XL expression, 
which in turn, prevents arsenic trioxide-triggered H9c2 cell death [187]. 
Finally, embryonic stem cell-derived cardiomyocytes were treated with high concentrations of glucose 
under hypoxia as an in vitro model for mimicking diabetes patients with cardiac ischemia. Under these 
conditions, there is an increase on the levels of hypoxia-inducing factor 1-α (HIF-1α) and BCL-2 
adenovirus E1B 19-kDa interacting protein 3 (BNIP3), which are hallmarks of hypoxia, and along with 
cleavage caspase-3 and cell death. Likewise, treatment with SalB decreases levels of HIF-1α and BNIP3, 
limits activation of caspase-3 and prevents apoptosis [188]. 
In rats, SalB had anti-apoptotic and cardioprotective activities of following I/R by dual specificity 
protein phosphatase (DUSP)-mediated regulation of the ERK1/2/JNK pathway [189]. In combination 
with ginsenoside, SalB exerts also cardioprotection against I/R Injury in rats. Comparing with same dose 
of SalB or ginsenoside only, SalB- ginsenoside showed more significant effects on down-regulation of 
myocardial infarct size, maintenance of myocardium structure, improvement on cardiac function, 
decrease of cytokine secretion including TNF-α, IL-1β, regulated on activation, normal T Cell expressed 
and secreted and the soluble cell adhesion molecules, sVCAM-1 [190]. Finally, a recent study revealed 
that SalB promotes neovascularization in the myocardium of ischemic rats [191]. Interestingly, in a rat 
model of isoproterenol-induced myocardial infarction, an oral pretreatment of vanillic acid, prevented 
an increase in creatine kinase-membrane bound in serum and diminished myocardial infarct size, 
showing the cardioprotective effect of the compound [192]. Moreover, vanillic acid prevented an 
alteration in lipid profile, induced a Bcl-2–associated X (BAX) expression decrease and a BCL-2 content 
increase [192]. This demonstrates a modulation of apoptosis signaling pathway and suggests that other 
cell death pathways (e.g. necrosis, necroptosis) have been prevented. Indeed, pharmacological inhibition 
of apoptosis and necroptosis would be more effective for cardioprotection [193, 194], but this remains 
to be investigated for vanillic acid. There are no described studies for phenolic acids supplementation in 




Plant lignans are polyphenolic substances derived from phenylalanine via dimerization of substituted 
cinnamic alcohols (see cinnamic acid), known as monolignols, to a dibenzylbutane skeleton. They are 
mainly found in various seeds, whole-grain cereals, and nuts but also to some extent in tea, vegetables, 
bread, coffee, fruit, and wine. A recent meta-analysis based on 3 independent studies do not reveal a 
positive impact on all-cause mortality and a contrasting impact on CVD [195-198]. Among the 4 dietary 
lignans identified, i.e. lariciresinol, pinoresinol, secoisolariciresinol, and matairesinol, only one pure 
compound, secoisolariciresinol was demonstrated to have potent angiogenic and antiapoptotic properties 
that may contribute to its cardioprotective effect in ex vivo and in vivo ischemic models (Table 9), 
putatively via increased protein expression of vascular endothelial growth factor (VEGF), Ang-1, and 
p-eNOS [199]. 
Moreover, dehydrosilybin, a flavonolignan from Silybum marianum (Carduus marianus) presented 
beneficial activities in cardiomyocytes (Table 9). In 2010, Gabrielová and colleagues demonstrated that 
low concentration of dehydrosilybin de-energized (decreasing mitochondrial potential) rat primary 
cultures of cardiomyocytes and attenuates rotenone-induced ROS formation [200]. Furthermore, in rat 
heart isolated mitochondria, it was verified by assessing oxygen consumption and mitochondrial 
potential that dehydrosilybin uncouples mitochondrial respiration and decreases mitochondrial ROS 
generation [200]. In a model of hypoxia/re-oxygenation dehydrosilybin also prevented cell death and 
oxidative stress in cardiomyocytes; in addition, dehydrosilybin treatment is associated with restored ratio 
of phosphorylated/total protein kinase C epsilon compared to injured cardiomyocytes [201]. 
6. Conclusion and perspectives  
Several pure polyphenol compounds present cytoprotective effects when directly administrated in 
cardiomyocyte cultures. The most described biological process affected by polyphenols is apoptosis and 
its prevention. Likewise, pure polyphenol compounds also modulate intracellular Ca2+ levels, hypoxia-
response pathways and autophagy. At the cellular level, polyphenol’s ability to target numerous proteins 
involved in cardiac remodeling such as CaMKK, Sirt1, BAX/BCL-2, PDEs, TRF2, eNOS as well as 
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SOD indicate that they can have multiple targets and complex effects. However, a key issue is the limited 
amount of information of polyphenol effects on structural proteins involved in cytoskeleton organization 
or proteins involved in excitation contraction-coupling, which have key roles in cardiac function. 
Moreover, consistent studies support a beneficial role of many pure polyphenols in treating various CVD 
in preclinical animal models, including I/R, myocardial infarction, LPS-induced cardiac dysfunction, 
hypertension, transverse aortic constriction, abdominal aortic constriction, diabetic cardiomyopathy and 
genetic models of cardiopathies. 
Cellular and in vivo approaches are very useful for molecular mechanisms description but present a 
limited physiological relevance. In particular, in what concerns polyphenol concentration reaching heart 
tissue and the exact compound composition, whether the original compound present in plants reach 
tissue or the compounds reaching are its metabolites or derivatives. These limitations clearly hamper the 
translation of the in vitro and in vivo findings to the clinics and consumers. An emerging approach is the 
use of synthetic optimized polyphenols to favor a rational pharmacological development of drug 
candidates. For example, a new derivative of caffeic acid, the N-propyl caffeamide, has already shown 
in vivo cardioprotective effects and a good pharmacokinetic profile of N-propyl caffeamide against IR 
injury [202]. 
For human, based on the discussed literature (see above), it is clear that the cardioprotective potential of 
polyphenols is currently promising and deserves future studies in healthy patients, as well as CVD 
patients and cancer patients to prevent cardiotoxic side effects of anticancer agents. However, to date, 
few studies exist proving the effects of pure or purified polyphenols on human CVD risk biomarkers. 
Mixed results exist for the majority of the polyphenolic subclasses with very few dose-response studies 
conducted so far. Some available evidence suggest that polyphenols may have synergistic effects with 
other food components that enhance their efficacy and bioavailability, but more studies with pure 
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Legend to figures 
Figure 1. Vicious circle of risk factors and cardiovascular diseases. Five cardiovascular risk factors have been 
identified by the world health organization (i.e. unhealthy diet, obesity, physical inactivity, tobacco, alcohol). They can 
be influenced by diverse determinants such as poverty, stress, aging, gender and hereditary factors. All these factors and 
determinants contribute individually or synergistically to the progression of CVD, including coronary ischemic diseases 
(CID), myocardial infarction (MI) and heart failure (HF). 
 
Figure 2. Classification of natural polyphenols. As a large and diverse family of compounds, polyphenols are into 4 
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Cellular models and primary cell 
cultures 
Animal model Humans 
Quercetin 
Models of cardiac injury or toxicity 
• ↑ viability [22] [23] [25]; 
• ↑PPAR- γ and AP-1 [26]; 
• ↓ TNF-α [22] ; 
• ↓ ROS overproduction [22]; 
• ↓ [Ca2+]i overload [22]; 
• ↓ phosphorylation of JNK, 
and p38 [23]; 
• ↓ phosphorylation of 
MAPK-APK-2 and cleaved 
caspase [25]; 
• ↓ hypertrophy [26] [30]; 
• inhibition of BAX and 
caspase-3 [23] 
Primary cell cultures 




Transverse aortic constriction 
rodent model  
• limited cardiac 
hypertrophy  [32-35] 
[36]; 
• prevented cardiac 
dysfunction and 
hypertension [32]; 
• ↓ Heart rate [35]; 
• ↓ Cardiomyocyte Ca2+ 
oscillation frequency 
[35]; 
• ↑ SOD and eNOS 
activity [38]; 




• ↓ SB 
pressure [40] 











Table 2-Cardioprotective evidence in cellular models and animal for the main studied flavones 
Compound Cellular models and primary cell cultures Animal model 
Apigenin 
 Lipoteichoic acid-induced inflammatory 
responsein rat cardiomyoblasts [53]: 
•  ↓ ERK ½, p38, JNK and AKT 
phosphorylation in a dose-dependent 
fashion;  
• ↓ NFκβ translocation and modulation of 
COX-2 and IL-1β transcription and 
translation 
ISO-induced myocardial 
toxicity in rats [54]: 









• inhibition of the ultrarapid delayed 
rectified potassium current and the 
transient outward K+ current [55]; 
• prolongs action potential duration in 
human atrial myocytes [55] 
Model of atrial fibrillation 





anesthetized dogs  
Scutellarin 
• ↑ cell proliferation  [46]; 
• ↑ expression of pro-survival proteins 
(BCL-2, VEGF, MM2 and MMP9) [46]; 
• ↓ Cytokines release (TNF- α, IL-1, IL-6 
and IL-8) [46]; 
• ↓ ROS and NO production [46]; 
• inhibition of high-glucose-induced 
monocyte endothelial cell adhesion [56]; 
• ↓ ICAM-1 and MCP-1 release [56]; 
• ↓ NF-kB expression [56] 
 
Model of Alloxan-induced 
diabetic mice  [56]: 















Table 3-Cardioprotective evidence in cellular models, animal and humans for the main studied flavanols 
Compound 
Cellular models and 
primary cell cultures 




• ↓ oxidative stress 
markers (↑ SOD and 
catalase activities) 
[59]; 
• ↓ ROS and Ca2+ 
levels [61]; 







pathway or via the 
phosphorylation of 
Stat1) [63] [64]; 







toxicity in rats [78]: 
• prevented cardiac damages 
by maintaining the balance 
of anti-apoptotic / pro-
apoptotic signaling 
proteins in the 
mitochondrial pathway of 
cell death; 
• ↓oxidative stress;  
• ↓ inflammation; 




• ↓ ROS and limiting 
DNA fragmentation 
[68]; 





channels activity [69] 
No studies No studies 
(−)-Epicatechin 
• ↓ cardiac hypertrophy 





hypertensive rat model [77]: 
• ↓ blood pressure;  
• ↑ iNOS activity and ↓ 
in superoxide 
production in left 
ventricle and aorta  
• acutely improve 
endothelial 
function in healthy 













Table 4-Cardioprotective evidence in cellular models, animal and humans for the main studied flavanones 
Compound 
Cellular models and primary 
cell cultures 
Animal model Humans 
Naringenin 
• ↓ apoptosis (↓ER stress; 
normalized BCL-2, BAX 
and caspase 3; ↓lipid 
oxidation;↑GSH;↑ATF6, 
IRE1α  and PERK for I/R 
insult and ↑ Akt,  Nrf2 and 
caspase 3 towards oxidative 
insult) in injured H9c2 cells 
[85] [86]; 
• Cellular model of senescent 
myocardial cells [87]:  
↓cellular senescence 
markers and modulate 
cardiac markers of aging-
induced damage; 
• Naringenin and naringenin-
7-O-glucoside Prevent 
DOX-induced cardiotoxicity 
[88] [30] [89] [90] 
Pressure-overload-induced cardio 
hypertrophy model [91]:  
↓ cardiac hypertrophy and 
interstitial fibrosis; 
↑ left ventricular function. 
↓PI3K/Akt, ERK and JNK 
signaling pathways  
 
Cardiorenal syndrome model 
[92]:  
↓ cardiac remodeling and 
cardiac dysfunction;  
↓ lipid profiles; 






• ↓ apoptosis through 
↑PI3K/Akt signalling 
pathway in primary cells 
after  H/R injury [93]; 
• ↓ apoptosis   in LPS-induced 
H9C2 cells via the JNK/Bax 
signalling pathway [94].   
I/R injury model [96]:  
↓inflammation, ↓oxidative 
stress, ↓myocardial apoptosis  
LAD occlusion in diabetic rats: 
Cardioprotective activity  
Left ventricular remodelling 
model [97]: 
↓inflammation, ↓myocyte 
apoptosis, attenuate cardiac 
dysfunction  
Pressure overload model [203]: 
↓myocyte apoptosis, 
attenuated cardiac 






 ↓oxidative stress, abnormal 
cellular morphology and 




















Table 5-Cardioprotective evidence in cellular models, animal and humans for the main studied isoflavones 
Compound 
Cellular models and primary 
cell cultures 
Animal model Humans 
Genistein 
• modulator of ionic 
channels mainly affecting 
Ca2+ signalling [104] 
[105] [106] [107]; 
• ↓ apoptosis (prevented 
mitochondrial membrane 
potential loss,  ↓ JNK, p38-
MAPK and caspase-3 
activation) preventing cell 
death against cardiotoxic 
arsenic trioxide [108];  
• ↓ER stress proteins, ↑BCL-
2, ↓BAX and caspase 3 in 
I/R injured H9c2 cells 
[109]; 
• Reverses glucose toxicity-
induced mechanical 
malfunction in myocytes, a 
diabetic cardiomyopathy 
model [109]; 
• Stimulates myocardial 
contractility by inhibition 
of TK pathway and PI3K 
activity [110] 




activity, serum and 
macrophages levels of 
TNF- , cardiac ICAM-1,↑ 
contractility  
Pressure-overload-induced 
cardio hypertrophy model [117] 
:  
↓ cardiac hypertrophy and 
interstitial fibrosis  
 
 
• ↓both SBP and DBP in 
hypertensive subjects, 
but not in normotensive 
individuals [121] and 
also in  RCT in post-
menopausal women 
with the metabolic 
syndrome  [126]; 
• ↑endothelial function 
[122]; 
•  improvements in blood 
lipids in 
postmenopausal 
women with type 2 






 ↓ ROS production;  
↓ activation of ERK1/2, p38 
and NF-κB , limiting cardiac 
hypertrophy [111]; 
 
• anti-hypertrophic by 
blocking of Rac1-
dependent NADPH oxidase 
activation and AP-1 [112];  
• block Na2+ currents in 
cardiomyocytes [113]; 
• antiapoptotic: ↑ BCL2-
associated athanogene 3 




Angiotensin II-induced heart 
hypertrophy model: 
↓ cardiac hypertrophy via the 
redox-sensitive ERK1/2, p38 
and NF-κB pathways in mice; 
restoring  ANP, BNP and β-
MHC expression in the left 
ventricles in vivo [111];  
↓ cardiac hypertrophy by ↑ 
Mir-15b/195 expression and 
suppressing non-canonical 
TGF signal pathway [119]; 
Improved endothelium-
dependent relaxation and 
reverted the changes in 
angiotensin II-induced protein 
expression of eNOS, TGF and 







Table 6-Cardioprotective evidence in cellular models, animal and humans for the main studied anthocyanins 
Compound 
Cellular models and primary 
cell cultures 
Animal model Humans 
Anthocyanins 
• Cyanidin and delphinidin, 
the most potent anthocyanins 
in the protection  against 
DOX cytotoxicity and ↓ lipid 
peroxidation  in   H9c2 
[130];  
• Delphinidin could target 
Stat1 on the basis of ex vivo 
I/R experiments [133]. 
• Cyanidin 3-glucoside 
from purple corn was 
shown to ameliorate 
DOX-induced 
cardiotoxicity by a 
histological 




































Table 7-Cardioprotective evidence in cellular models, animal and humans for the main studied stilbenes 
Compound 
Cellular models and 
primary cell cultures 
Animal model Humans 
Resveratrol 
• ↓hypertrophy (↓ANP 
and cell surface) in 
primary cultures [205, 
206]; 
 
• ↓apoptosis (↓ caspase-




34a) in primary cells 
and cell lines [145], 
[146], [147], [148], 
[150], [151], [152]; 
 
• Antiarrhythmic role 
(↓cardiac voltage-gated 
sodium channels)in 





1β)in RNVC [146]; 
 
• ↓hyperglycemia-





• Modulates autophagy 
(via SIRT1)[153] 
• Atherosclerosis rodent models 
[155]: 
Protection against oxidation, 
inflammation, platelet 
oxidation and thrombus 
formation;  
• Sepsis-induced cardiac 
dysfunction model [156]: 
Protection by enhancing 




cardiomyopathy model [157]: 
↓pathological cardiac 
remodeling (myocardial 
fibrosis) and improvement of 
cardiac function 
Reestablishment of calcium 
homeostasis;  
• Age-related metabolic and 
cardiac phenotype model [158]: 
↓cyclic nucleotides 
phosphodiesters, e.g. PDE4  
↑NAD+ and SIRT1 activity 
(↑intracellular 
calcium;↑CaMKKβ-AMPK 
pathway; ↑ryanodine receptor 
calcium release channel); 
• Diabetic cardiomyopathy model: 
↓apoptosis; improve cardiac 
function, ↓ER stress (via 
SIRT1) [150]; 
• Hypertension models: 
↓Inflammation and oxidative 
stress (SIRT1, AMPK, Nrf2, 
NF-κB, eNOS) [143] 
↓hypertrophy and improve 
cardiac contractility [162] 
 
• ↓systolic BP [163]; 




• ↑glucose control and 
↑insulin sensitivity but 
only in diabetic patients 
[165]; 









SIRT1) in primary 
cells and isolated rat 
hearts [154] 
No studies No studies 
Pterostilbene 
• ↓cell death (via SIRT1) 




Table 8- Cardioprotective evidence in cellular models and animal for the main studied phenolic acids 
Compound Cellular models and primary cell cultures Animal model 
Gallic acid 
• ↓hypertrophy (↑ sarcomere organization, 
↓β-myosin heavy chain, ↓ANP and BNP) 
in cell lines and primary cells [170]; 




• ↓calcium currents (via modulation of 
nitric oxide-guanylate cyclase-cGMP 
pathways] in primary cells [172] 
No studies 
Caffeic acid 





• ↓ROS in primary cells [173]; 




• ↓apoptosis (↓caspase-3) and ↑ Akt 
phosphorylation in primary cells [177]; 
• ↓inflammation (via NF-κB pathway 
inhibition [178] 
Myocardial I/R injury model [177]:  
• ↓inflammation, ↓platelet aggregation, 
↓cardiomyocytes apoptosis  
 
Ferulic acid 
• ↓apoptosis (interruption of ERKs 
signaling) in cell lines [181];  
• ↑cell survival (↓intracellular calcium 
overload via nitric oxide/cGMP/PKC 
pathway) in primary cells [182] 
Hypertensive model [180]: 
• Anti-inflammatory, platelet 
aggregation inhibitor, 
antihypertensive, anti-apoptotic  
Salvianolic 
acid B 
• ↓hypertrophy (↓PARP-1) in primary cells 
[183];  
• ↓ROS (↓NADPH 2 and 4)  in primary 
cells [183]; 
• ↓inflammation and cell death ( via TLR4-
NF-κB-TNFα pathway) in primary cells 
[184]; 
 
• ↓autophagy  and ↓apoptosis (↑miR-30a, 
↑PI3K/Akt pathway) in cell lines and 
primary cells [185] [186] [187]; 
• ↓↓high glucose/ hypoxia-induced HIF-1α 
and BNIP3, ↓apoptosis (↓caspase-3) [188] 
 
I/R injury model:  
• ↓apoptosis (via DUSP-mediated 
regulation of ERK1/2/JNK) 
[189]; 
• in combination with 
Ginsenoside, ↓myocardial 
infarct size, maintenance of 
myocardial structure and 
improvement of cardiac function 
[176]; 
• in combination with 
Ginsenoside ↓ of cytokines’ 
secretion  (TNF-α, IL-1β, 
RANTES, sVCAM-1) [190]; 




 Myocardial infarction model [192]:  
• ↓creatine kinase-membrane bound in 
serum and ↓myocardial infarct size; 




Table 9- Cardioprotective evidence in cellular models, animal and humans for the main studied lignans 
Compound 
Cellular models and primary cell 
cultures 
Animal model Humans 
Secoisolariciresinol 
No studies Myocardial ischemic 





• No positive impact of 
lignans on all-cause 
mortality and a 
contracting impact on 
CVD  [195] [196] [197] 
[198] 
Dehydrosilybin 
• ↓mitochondrial potential, 
uncouples mitochondrial 
respiration and ↓mitochondrial 
ROS in rat heart isolated 
mitochondria and primary 
cultures [200]; 
• ↓cell death and ROS in primary 
cells [201]; 
• Restored the ration of 
phosphorylated/total protein 
kinase C epsilon in primary 
cultures [201] 
No studies No studies 
 
 
 
